The COVID-19 healthcare crisis is spreading beyond just those with the virus. As millions of Americans lose their jobs, they also stand to lose the employer-provided health insurance they rely on for life-saving drugs. Without insurance, the costs of those drugs can skyrocket. Insulin alone can cost $12,000 a year. So what can be done to keep insulin affordable during the crisis? One solution might come from a novel legal strategy that would test the limits of what constitutes illegal price gouging.
Previous article South African Competition Commission reveals wide scope of buyer power provisions Next article What happens if Congress overrides the classic antitrust platform market case of American Express